RE:PBI 4547, for diabetes - Huge Market PotentialGreat posts, Biofinder. It is clear that PLI's R&D department is working hard and getting good results. While it is important to have the next generation of drug candidates in hand, I really wish that PLI would prioritise resources and focus on getting a couple of applications of 4050 across the line (i.e. IPF;cystic fibrosis;Alstrom). Armed with cashflow, the company can explore further the many potential applications of 4050 and its derivatives. 'Show me the money' must be the new mantra of PLI shareholders.